| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
TNF-alpha
REN-1189's primary target is the pro-inflammatory cytokine TNF-α. It functions as an intracellular inhibitor of the p38 mitogen-activated protein kinase (MAPK) phosphoactivation. By inhibiting this pathway, it reduces the release of TNF-α, which is a key mediator of neuroinflammation and neuronal damage. |
|---|---|
| ln Vitro |
In vitro, REN-1189 inhibits TNF-α release. It inhibits the p38 MAPK pathway, which is upstream of TNF-α production. Its neuroprotective effects are studied in cellular models of neurotoxicity.
|
| ln Vivo |
In vivo, REN-1189 has been studied as a candidate neuroprotective agent for patients with HIV-related central nervous system diseases. Its antioxidant and neuroprotective activities suggest it could be beneficial in mitigating the neurotoxic effects of HIV infection.
|
| Enzyme Assay |
The activity of REN-1189 is assessed by measuring its ability to inhibit TNF-α release in cell-based assays. In these experiments, immune cells are stimulated (e.g., with lipopolysaccharide) to produce TNF-α, and the effect of the compound on the amount of cytokine released is measured by ELISA.
|
| Cell Assay |
For cellular assays, microglial or neuronal cell lines are used. Cells are treated with REN-1189, and the levels of phosphorylated p38 MAPK are measured by Western blot to confirm target engagement. Its neuroprotective effect can be assessed by measuring cell viability following a toxic insult.
|
| Animal Protocol |
In vivo studies for REN-1189 would be performed in animal models of neuroinflammation, such as the HIV-1 transgenic rat model. The compound would be administered, and its effect on neuroinflammation and neuronal function would be assessed.
|
| ADME/Pharmacokinetics |
REN-1189 has a molecular weight of 386.43 g/mol.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for REN-1189 is not available in the search results. As a research compound, its safety profile is not fully established.
|
| References | |
| Additional Infomation |
CPI-1189 has been used in research trials investigating treatments for HIV infection and AIDS-related dementia.
REN-1189 (CPI-1189) is a research compound that has been investigated for its potential in neuroprotection. Its ability to inhibit TNF-α release and its antioxidant properties make it a candidate for treating conditions associated with neuroinflammation, such as HIV-associated neurocognitive disorders (HAND). It is not an approved drug. |
| Molecular Formula |
C13H18N2O2
|
|---|---|
| Molecular Weight |
234.299
|
| Exact Mass |
234.136
|
| Elemental Analysis |
C, 66.64; H, 7.74; N, 11.96; O, 13.66
|
| CAS # |
183619-38-7
|
| Related CAS # |
183619-38-7
|
| PubChem CID |
151118
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
458.3±28.0 °C at 760 mmHg
|
| Flash Point |
183.9±24.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.553
|
| LogP |
1.38
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
286
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C
|
| InChi Key |
DJKNRCWSXSZACF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)
|
| Chemical Name |
4-acetamido-N-tert-butylbenzamide
|
| Synonyms |
CPI-1189; REN 1189; REN 1654; REN-1189; REN1654; REN-1654; REN1189; CPI1189; CPI 1189
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 47~100 mg/mL (200.6~426.8 mM)
Ethanol: ~15 mg/mL (~64.0 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2680 mL | 21.3402 mL | 42.6803 mL | |
| 5 mM | 0.8536 mL | 4.2680 mL | 8.5361 mL | |
| 10 mM | 0.4268 mL | 2.1340 mL | 4.2680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00002209 | Completed | Drug: CPI-1189 | HIV Infections AIDS Dementia Complex |
Centaur Pharmaceuticals | Not Provided | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA